Platelet kinetics

Current Opinion in Hematology

Volumn 4, Issue 5, 1997, Pages 330-334

  Dale, George L ^a  

^a UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL MARKER; CYTOKINE; INTERLEUKIN 6; MESSENGER RNA; RADIOISOTOPE; THIAZOLE ORANGE;

CELL AGING; CELL KINETICS; CELL SURVIVAL; HUMAN; HUMAN CELL; PRIORITY JOURNAL; SHORT SURVEY; STAINING; TECHNIQUE; THROMBOCYTE; THROMBOCYTE LIFESPAN; THROMBOCYTOPENIA; THROMBOCYTOPOIESIS;

EID: 0030880418     PISSN: 10656251     EISSN: None     Source Type: Journal    
DOI: 10.1097/00062752-199704050-00006     Document Type: Short Survey

References (60)

1. George JN, Dale GL: Platelet kinetics. In Williams Hematology, edn 5. Edited by Beutler E, Lichtman MA, Coller BS, Kipps TJ. New York: McGraw-Hill; 1994:1202-1205.
2. Rodrigues M, Sinzinger H: Platelet labeling: methodology and clinical applications. Thromb Res 1994, 76:399-432.
3. Paulus JM, Aster RH: Clinical evaluation of thrombokinetics. In Hematology, edn 4. Edited by Williams WJ, Beutler E, Erslev AJ, Lichtman MA. New York: McGraw Hill; 1990:1260-1266.
4. Dale GL: Platelet turnover. In Thrombosis and Hemorrhage, edn 2. Edited by Loscalzo J, Schafer AI. Baltimore: Williams & Wilkins; 1997, in press.
5. International Committee for Standardization in Hematology: Panel on diagnostic applications of radionuclides. Recommended methods for indium-111 platelet survival studies. J Nucl Med 1988, 29:564-566.
6. Stuart MJ, Murphy S, Oski FA: A simple nonradioisotope technic for the determination of platelet life span. N Engl J Med 1975, 292:1310-1313.
7. Chamberlain KG, Tong M, Chiu E, Pennington DG: The relationship of human platelet density to platelet age: platelet population labeling by monoamine oxidase Inhibition. Blood 1989, 73:1218-1225.
8. Chamberlain KG, Tong M, Chiu E, Penington DG: The use of monoamine oxidase Inhibition to estimate megakaryocyte-platelet regeneration time. Thromb Res 1988, 49:425-435.
9. Catalano PM, Smith JB, Murphy S: Platelet recovery from aspirin inhibition in vivo: Differing patterns under various assay conditions. Blood 1981, 57:99-105.
10. Harker LA: Platelet survival time: Its measurement and use. Prog Hemost Thromb 1978, 4:321-347.
11. Heilmann E, Friese P, Anderson S, George JN, Hanson SR, Burstein SA, Dale GL: Biotinylated platelets: a new approach to the measurement of platelet life span. Br J Haematol 1993, 85:729-735.
12. Franco RS, Lee KN, Barker-Gear R, Gates R, Menitove JE: Use of bi-level biotinylation for concurrent measurement of in vivo recovery and survival in two rabbit platelet populations. Transfusion 1994, 34:784-789.
13. Dale GL, Wolf RF, Hynes LA, Friese P, Burstein SA: Quantitation of platelet life span in splenectomized dogs. Exp Hematol 1996, 24:518-523.
14. Peng J, Friese P, Heilmann E, George JN, Burstein SA, Dale GL: Aged platelets have an impaired response to thrombin as quantitated by P-selectin expression. Blood 1994, 83:161-166.
15. Manning KL, Novinger S, Sullivan PS, McDonald TP: Successful determination of platelet life span in C3H mice by in vivo biotinylation. Lab Anim Sci 1996, 46:545-548.
16. Dale GL, Gaddy P, Pikul FJ : Antibodies against biotinylated proteins are present In normal human sera. J Lab Clin Med 1994, 123:365-371.
17. Cordle DG, Strauss RG, Lankford G, Mock DM: Antibodies provoked by transfusion of biotin-labeled red blood cells. Transfusion 1996, 36(suppl):46S.
18. Franco RS, Lohmann J, Silberstein EB, Mayfield-Pratt G, Rucknagel DL, Joiner CH, Weiner M: The use of biotinylated RBC to determine the in vivo survival characteristics of normal and sickle cells. Blood 1996, 88:11a.
19. Jacobs RM, Boyce JT, Kociba GJ: Flow cytometric and radioisotopic determinations of platelet survival time in normal cats and feline leukemia virus-Infected cats. Cytometry 1986, 7:64-69.
20. Michelson AD, Barnard MR, Hechtman HB, MacGregor H, Connolly RJ, Loscalzo J, Valeri CR: In vivo tracking of platelets: circulating degranulated platelets rapidly lose surface P-selectin but continue to circulate and function. Proc Natl Acad Sci U S A 1996, 93:11877-11882. Platelets labeled with PKH2, a fluorescent membrane marker, for flow cytometric monitoring of short-term cell survival.
21. Slezak SE, Horan PK: Fluorescent In vivo tracking of hematopoietic cells: part I. Technical considerations. Blood 1989, 74:2172-2177.
22. Ingram M, Coopersmith A: Reticulated platelets following acute blood loss. Br J Haematol 1969, 17:225-229.
23. Kienast J, Schmitz G: Flow cytometric analysis of thiazole orange uptake by platelets: a diagnostic aid in the evaluation of thrombocytopenic disorders. Stood 1990, 75:116-121.
24. Lee LG, Chen CH, Chiu LA: Thiazole orange: a new dye for reticulocyte analysis. Cytometry 1986, 7:508-517.
25. Watanabe K, Takeuchi K, Kawai Y, Ikeda Y, Kubota F, Nakamoto H: Automated measurement of reticulated platelets in estimating thrombopoiesis. Eur J Hematol 1995, 54:163-171.
26. Dale GL, Friese P, Hynes LA, Burstein SA: Demonstration that thiazole orange-positive platelets In the dog are less than twenty-four hours old. Blood 1995, 85:1822-1825.
27. Ault KA, Knowles C: In vivo biotinylation demonstrates that reticulated platelets are the youngest platelets in circulation. Exp Hematol 1995, 23:996-1001.
28. Richards EM, Baglin TP: Quantitation of reticulated platelets: methodology and clinical application. Br J Haematol 1995, 91:445-451.
29. Chavda N, Mackie IJ, Porter JB, Harrison P, Patterson K, Machin SJ: Rapid flow cytometric quantitation of reticulated platelets In whole blood. Platelets 1996, 7:189-194.
30. Rinder HM, Bonan JL, Anandan S, Rinder CS, Rodrigues PA, Smith BR: Noninvasive measurement of platelet kinetics in normal and hypertensive pregnancies. Am J Obstet Gynecol 1994, 170:117-122.
31. Tomer A, Hanson SR, Harker LA: Autologous platelet kinetics in patients with severe thrombocytopenia: discrimination between disorders of production and destruction. J Lab Clin Med 1991, 118:546-554.
32. Peterec SM, Brennan SA, Rinder HM, Wnek JL, Beardsley DS: Reticulated platelet values In normal and thrombocytopenic neonates. J Pediatr 1996, 129:269-274.
33. Rakoczi I, Tallian F, Bagdany S, Gati I: Platelet life span in normal pregnancy and pre-eclampsia as determined by a non-radioisotopic technique. Thromb Res 1979, 15:553-556.
34. Janes SL, Kyle PM, Redman C, Goodall AH: Flow cytometric detection of activated platelets In pregnant women prior to the development of pre-eclampsia. Thromb Haemost 1995, 74:1059-1063.
35. Ault KA, Rinder HM, Mitchell J, Carmody MB, Vary CPH, Hillman RS: The significance of platelets with Increased RNA content (reticulated platelets). Am J Clin Pathol 1992, 98:637-646.
36. Bonan JL, Rinder HM, Smith BR: Determination of the percentage of thiazole orange (TO)-positive, "reticulated" platelets using autologous erythrocyte TO fluorescence as an Internal standard. Cytometry 1993, 14:690-694.
37. Mezzano D, Del Pino GE, Montesinos M, Garcia ME, Aranda E, Foradori A: Platelet 5-hydroxytryptamine increases with platelet age In dogs. Thromb Haemost 1991, 66:254-258.
38. Aranda E, Pizarro M, Pereira J, Mezzano D: Accumulation of 5-hydroxytryptamine by aging platelets: studies In a model of suppressed thrombopolesis In dogs. Thromb Haemost 1994, 71:488-492.
39. Aranda E, Pereira J, Ajenjo C, Prieto C, Sepúlveda S, Mezzano D: Human Intraplatelet 5-hydroxytryptamine Is correlated with mean platelet survival time. Thromb Res 1996, 84:67-72.
40. Harker LA: The kinetics of platelet production and destruction in man. Clin Haematol 1977, 6:671-693.
41. Winocour PD: Platelet turnover In advanced diabetes. Eur J Clin Invest 1994, 24(suppl 1):34-37.
42. Ritchie JL, Harker LA: Platelet and fibrinogen survival in coronary atherosclerosis. Am J Cardiol 1977, 39:595-598.
43. Najean Y, Rain JD: The mechanism of thrombocytopenia in patients with HIV infection. J Lab Clin Med 1994, 123:415-420.
44. Aster RH: Pooling of platelets In the spleen: role In the pathogenesis of hypersplenic thrombocytopenia. J Clin Invest 1966, 45:645-657.
45. Kutti J, Safai-Kutti S: In vitro labeling of platelets: an experimental study on healthy asplenic subjects using two different incubation media. Br J Haematol 1975, 31:57-64.
46. Hill-Zobek RL, McCandless B, Kang SA, Chikkappa G, Tsan MF: Organ distribution and fate of human platelets: studies of asplenic and splenomegalic patients. Am J Hematol 1986, 23:231-238.
47. Heyns ADP, Lotter MG, Badenhorst PN, van Reenen O, Pieters H, Minnaar PC: Kinetics and fate of In-111-oxine labelled blood platelets In asplenic subjects. Thromb Haemost 1980, 44:100-104.
48. Burstein SA, Peng J, Friese P, Wolf RF, Harrison P, Downs T, Hamilton KK, Comp PC, Dale GL: Cytokine-induced alteration of platelet and hemostatic function. Stem Cells 1996, 14(suppl 1):154-162.
49. Nash RA, Burstain SA, Storb R, Yang WJ, Abrams K, Appelbaum FR, Boone T, Deeg HJ, Durack LK, Schuening FG, et al.: Thrombocytopenia In dogs induced by granulocyte-macrophage colony-stimulating factor: Increased destruction of circulating platelets. Blood 1995, 86:1765-1775.
50. Hallett MB, Lloyds D: Neutrophil priming: the cellular signals that say 'amber' but not 'green.' Immunol Today 1995, 16:264-268.
51. Tomer A, Stahl CP, McClure HM, Anderson DC, Myers LA, Liehl E, Winton EF: Effects of recombinant human granulocyte-macrophage colony-stimulating factor on platelet survival and activation using a nonhuman primate model. Exp Hematol 1993, 21:1577-1582.
52. Aglietta M, Monzeglio C, Sanavio F, Apra F, Morelli S, Stacchini A, Piacibello W, Bussolino F, Bagnara GP, Zauli G, el al.: In vivo effect of granulocyte-macrophage colony stimulating factor on megakaryocytopoiesis. Blood 1991, 77:1191-1194.
53. Stahl CP, Winton EF, Monroe MC, Holman RC, Zelasky M, Liehl E, Myers LA, McClure H, Anderson D, Evatt BL: Recombinant human granulocyte-macrophage colony-stimulating factor promotes megakaryocyte maturation In nonhuman primates. Exp Hematol 1991, 19:810-816.
54. Peng J, Friese P, Wolf RF, Harrison P, Downs T, Lok S, Dale GL, Burstein SA: Relative reactivity of platelets from thrombopoietin- and interleukin-6-treated dogs. Blood 1996, 87:4158-4163. It has been documented in dogs that young platelets produced in response to interleukin-6 are hyperreactive to thrombin as compared with age-matched cells from control animals. Thrombopoietin treatment results in young platelets with normal reactivity toward thrombin.
55. Oda A, Miyakawa Y, Druker BJ, Ozaki, Yabusaki K, Shirasawa Y, Handa M, Kato T, Miyazaki H, Shimosaka A, Ikeda Y: Thrombopoletin primes human platelet aggregation induced by sheer stress and by multiple agonists. Stood 1996, 87:4664-4670.
56. Kubota Y, Arai T, Tanaka T, Yamaoka G, Kiuchi H, Kajikawa T, Kawanishi K, Ohnishi H, Yamaguchi M, Takahara J, Irino S: Thrombopoietin modulates platelet activation In vitro through protein-tyrosine phosphorylation. Stem Cells 1996, 14:439-444.
57. Rodriguez-Liñares B, Watson SP: Thrombopoietin potentiates activation of human platelets in association with JAK2 and TYK2 phosphorylation. Biochem J 1996, 316:93-98.
58. Harker LA, Hunt P, Marzec UM, Kelly AB, Tomer A, Hanson SR, Stead RB: Regulation of platelet production and function by megakaryocyte growth and development factor in nonhuman primates. Blood 1996, 87:1833-1844.
59. Harker LA, Marzec UM, Hunt P, Kelly AB, Tomer A, Cheung E, Hanson SR, Stead RB: Dose-response effects of pegylated human megakaryocyte growth and development factor on platelet production and function in nonhuman primates. Blood 1996, 88:511-521.
60. Oleksowicz L, Puszkin E, Mrowiec Z, Isaacs R, Dutcher JP: Alterations in platelet function in patients receiving interleukin-6 as cytokine therapy. Cancer Invest 1996, 14:307-316.